Omada Health, Inc. $OMDA Shares Acquired by Quantinno Capital Management LP

Posted by George Bondi on Aug 19th, 2026

Quantinno Capital Management LP boosted its holdings in Omada Health, Inc. (NASDAQ:OMDA – Free Report) by 464.1% in the first quarter, HoldingsChannel reports. The firm owned 58,723 shares of the company’s stock after purchasing an additional 48,313 shares during the period. Quantinno Capital Management LP’s holdings in Omada Health were worth $738,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of OMDA. Quarry LP acquired a new position in shares of Omada Health in the 4th quarter valued at approximately $29,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Omada Health during the fourth quarter worth approximately $32,000. Raymond James Financial Inc. bought a new stake in shares of Omada Health in the second quarter worth $32,000. Strs Ohio raised its holdings in Omada Health by 151.0% in the fourth quarter. Strs Ohio now owns 4,267 shares of the company’s stock valued at $67,000 after acquiring an additional 2,567 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new position in Omada Health during the 4th quarter valued at $73,000.

Insider Buying and Selling at Omada Health

In other news, CEO Sean P. Duffy sold 12,942 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $24.81, for a total transaction of $321,091.02. Following the completion of the transaction, the chief executive officer directly owned 411,861 shares of the company’s stock, valued at approximately $10,218,271.41. This represents a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Wei-Li Shao sold 8,866 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.02, for a total value of $221,827.32. Following the sale, the president owned 307,372 shares in the company, valued at $7,690,447.44. The trade was a 2.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 254,726 shares of company stock worth $5,370,496 in the last ninety days. Insiders own 6.38% of the company’s stock.

Omada Health Price Performance

OMDA stock opened at $23.75 on Wednesday. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of 475.00 and a beta of 1.73. Omada Health, Inc. has a 1-year low of $10.28 and a 1-year high of $26.92. The firm has a fifty day moving average price of $21.21 and a two-hundred day moving average price of $16.60.

Omada Health (NASDAQ:OMDA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The company had revenue of $87.83 million for the quarter, compared to the consensus estimate of $80.93 million. As a group, analysts expect that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on OMDA shares. Wall Street Zen raised shares of Omada Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. BTIG Research increased their price target on shares of Omada Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings upgraded Omada Health from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Citizens Jmp boosted their price objective on Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a report on Friday, August 14th. Finally, Barclays increased their target price on Omada Health from $20.00 to $25.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Omada Health has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Read Our Latest Stock Report on Omada Health

Omada Health Company Profile

(Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.